botensilimab,balstilimab
agenus
$agen ~ 23.91%, = immuno-#oncology w/ thrps dsgnd to activate immune rspns to #cancers /infections, says at #esmo it expanded data from phase 1b stdy of #botensilimab and #balstilimab in ptnts w/ microsatellite stable colorectal cancer. #acfview #biotechnology remains healthy. 